Aerie Pharmaceuticals Incの資産のリターン
Aerie Pharmaceuticals Incの資産のリターン は何ですか。
Aerie Pharmaceuticals Incの資産のリターン は-9.21%です。
資産のリターン の定義は何ですか。
資産のリターンは 、企業の資産が収益を生み出す際の収益性を示します。純利益を平均総資産で除して計算されます。
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
NASDAQのセクタHealth Careにおける資産のリターン の企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似の資産のリターン
- ModivCareの資産のリターン は-9.22%です。
- NexGen Ltdの資産のリターン は-9.22%です。
- QuinStreet Incの資産のリターン は-9.22%です。
- Winfullの資産のリターン は-9.22%です。
- Sri Adhikari Brothers Television Networkの資産のリターン は-9.21%です。
- QMC Quantum Minerals Corpの資産のリターン は-9.21%です。
- Aerie Pharmaceuticals Incの資産のリターン は-9.21%です。
- Tree House Education & Accessoriesの資産のリターン は-9.20%です。
- Star Equityの資産のリターン は-9.20%です。
- eSunの資産のリターン は-9.18%です。
- Xinji Shaxi Co., Ltdの資産のリターン は-9.18%です。
- BCM Resourcesの資産のリターン は-9.18%です。
- Arbor Metalsの資産のリターン は-9.18%です。